The FDA's approval of Actavis' generic Adderall XR will be a positive for Watson Pharmaceuticals (WPI +1%), which is acquiring the company, says Goldman. The firm says the news supports its above consensus earnings estimates, adding that it sees only modest impact to TEVA and IPXL.
The FDA's approval of Actavis' generic Adderall XR will be a positive for Watson Pharmaceuticals...
From other sites
Video at CNBC.com (Thu, 5:00PM)
Video at CNBC.com (Wed, 6:25PM)
Video at CNBC.com (Tue, 3:28PM)
Video at CNBC.com (Tue, 2:25PM)
Video at CNBC.com (Sep 13, 2016)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs